Pharmaceuticals
CStone received China NMPA IND approval for CS2006/NM21-1480, a PD-L1/4-1BB/HSA multi-specific antibody, marking further expansion of its Pipeline 2.0
SUZHOU, China, Sept. 15, 2021 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on the research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, today announced that the investigational ne...
2021-09-15 08:30
3839
New Therapy to Treat Advanced Small Cell Lung Cancer Approved for Australian Patients
Highlights: * ZEPZELCA® (lurbinectedin) is the first new therapy approved to treat second-line metastatic SCLC inAustralia in more than 20 years * * ZEPZELCA approval granted under a provisional regulatory pathway * US FDA and TGA collaborated via 'Project Orbis' to accelerate avail...
2021-09-14 18:57
2268
BioVaxys Bioproduction Partner WuXi Biologics Completes Synthesis Of Recombinant SARS-CoV-2 s-proteins for BVX-0320 and CoviDTH Programs
VANCOUVER, BC, Sept. 14, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys"), announced today that global CDMO partner WuXi Biologics, has completed the synthesis of recombinant SARS-CoV-2 s-protein for BVX-0320, the company's COVID-19 vaccine candida...
2021-09-14 15:00
6491
Jemincare group has completed the Phase I clinical trial of its anti-SARS-CoV-2 neutralizing antibody JMB2002
SHANGHAI, Sept. 14, 2021 /PRNewswire/ -- Recently, Jemincare group has declared that it has completed phase I clinical trial of self-developed novel coronavirus specific neutralizing antibody (Project code: JMB2002). The clinical trial of JMB2002 was stated in January 2021. A single-center, rand...
2021-09-14 11:43
4757
Eleva Reaches Industrial Production Scale and Prepares for Clinical Development of Factor H
FREIBURG, Germany, Sept. 14, 2021 /PRNewswire/ -- Eleva, a manufacturer of superior biologics, is scaling up its production capacity to 2500 l in state-of-the-art single-use reactors. This will produce enough factor H to cover all three clinical phases. Eleva has ordered four more state-of-the-a...
2021-09-14 10:30
2278
CStone presents updated data from registrational clinical study of sugemalimab in patients with stage IV NSCLC in an oral presentation at IASLC 2021 WCLC
* Data with the longer follow-up showed that sugemalimab plus chemotherapy continued to demonstrate improvement in progression-free survival (PFS), after the primary efficacy endpoint was met at an interim PFS analysis last year * The updated data showed that the risk of disease progression or...
2021-09-14 08:30
5254
Global Investors Invest in Etana
JAKARTA, Indonesia, Sept. 14, 2021 /PRNewswire/ -- PT Etana Biotechnologies Indonesia (Etana)has secured a new round of investment led by Legend Capital along with Innovent Biologics, Inc. (Innovent) (HKEX: 01801), and a consortium led by UOB Venture Management (UOBVM). This round of funds will b...
2021-09-14 08:00
7633
PharmAbcine to Participate in ACCESS CHINA Biotech Forum
DAEJEON, South Korea, Sept. 13, 2021 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next generation antibody therapeutics, announced today that the Company will virtually participate in ACCESSCHINA Biotech Forum. The event will...
2021-09-13 20:00
1880
I-Mab Added to FTSE ESG Index Series
SHANGHAI and GAITHERSBURG, Md., Sept. 13, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that I-Mab will be added to the following FTSE ESG (Env...
2021-09-13 20:00
5209
RedHill Biopharma Accelerates Ongoing U.S. Phase 2/3 COVID-19 Study of Once-Daily Oral RHB-107 in Non-Hospitalized Patients with South African Approval
The South African Health Products Regulatory Authority (SAHPRA) has approved the Phase 2/3 study of once-daily orally-administered RHB-107 (upamostat) for patients with symptomatic COVID-19 who do not require hospital care Number of U.S. sites for the study has also been expanded RHB-107, a nov...
2021-09-13 19:00
6982
Hummingbird Bioscience Announces US FDA Clearance of IND for First-in-Human Phase 1 Trial of HMBD-002 in Patients with Advanced Solid Tumors
HOUSTON and SINGAPORE, Sept. 13, 2021 /PRNewswire/ -- Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets, today announced that the U.S. Food and Drug Administration (FDA) has approved the initiation of a Phas...
2021-09-13 17:00
2204
Everest Medicines Enters into Comprehensive Agreements with Providence Therapeutics to Advance mRNA Vaccines and Therapies, including COVID-19 Vaccines, in Asia Emerging Markets
SHANGHAI, Sept. 13, 2021 /PRNewswire/ -- Everest Medicines Limited
2021-09-13 17:00
5670
Samsung Biologics Joins Frontier 1.5D Project as part of 2050 Carbon Neutral Initiative
INCHEON, South Korea, Sept. 13, 2021 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), the world's leading contract development and manufacturing organization, announced the signing of an MOU today to participate in the Frontier 1.5D initiative to develop a climate risk management model as part...
2021-09-13 12:41
2642
Kazia Therapeutics to Present at HC Wainwright 23rd Annual Global Investment Conference
SYDNEY, Sept. 10, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that CEO, DrJames Garner, will be presenting at the HC Wainwright 23rd Annual Global Investment Conference, to be held virtually from13-...
2021-09-11 00:30
20975
Senhwa Announces First Patient Successfully Dosed in Phase 1b Expansion Study of Pidnarulex to Treat Solid Tumors with Specific Homologous Recombination Gene Mutations
TAIPEI and SAN DIEGO, Sept. 10, 2021 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and novel coronaviruses, announced t hat their first patient has been successfully dosed, in a Phase1b c...
2021-09-10 19:00
15899
Cytiva triples single-use consumables capacity in China
* Three new manufacturing lines were successfully launched in under ten months, with an additional eight new lines planned to launch in Q3 2022. * Sustain and secure the supply chain for customers in China and the broader region. * With the use of Fortem™ film, Cytiva helps customers speed...
2021-09-10 16:33
4067
Yuyu Pharma Receives ISO 37001 Anti-Bribery Management System Certification
SEOUL, South Korea, Sept. 9, 2021 /PRNewswire/ -- Yuyu Pharma (KRX: 000220) received the ISO 37001 Anti-Bribery Management System (ABMS) certification from the British Standards Institution (BSI) inAugust 2021. Chief Executive Officer Robert Wonsang Yu said "we believe that the certification is a...
2021-09-09 21:00
3406
Clover Biopharmaceuticals Receives Pharmaceutical Manufacturing Permit from Zhejiang Medical Products Administration to Produce COVID-19 Vaccine
CHENGDU, China, Sept. 9, 2021 /PRNewswire/ -- Clover Biopharmaceuticals, Ltd.
(Clover)
2021-09-09 19:51
3199
B dot Medical Successfully Develops Compact Scanning Magnet for Proton Cancer Therapy System
TOKYO, Sept. 9, 2021 /PRNewswire/ -- B dot Medical Inc. has conducted an energization test of the scanning magnet, which is designed and manufactured at its factory, for a compact proton cancer therapy system under development, and confirmed the generation of a magnetic field. That means a major ...
2021-09-09 15:00
1953
Gan & Lee Pharmaceuticals to present data at the 57th Annual European Association for the Study of Diabetes Meeting
BEIJING and BRIDGEWATER, N. J., Sept. 9, 2021 /PRNewswire/ -- Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee, stock code: 603087.SH), is excited to present positive data from five abstracts which will be featured as short oral discussions at the 57th Annual European Ass...
2021-09-09 15:00
3321
Week's Top Stories
Most Reposted
Ascentium Welcomes MGI Dobbyn Carafa, Strengthening Advisory Capability in Australia
[Picked up by 297 media titles]
2026-07-20 15:00
A New Chapter Begins: Peach Blossoms Returns to Level 5 with the Debut of its Black Pearl One Diamond Tasting Journey
[Picked up by 295 media titles]
2026-07-23 16:00
Singapore Tourism Board and Traveloka Renew Partnership to Welcome More Southeast Asian and Australian Travellers to Singapore
[Picked up by 291 media titles]
2026-07-17 18:18
MetaOptics to Deploy its Direct Laser Writer at the University of Arizona's Center of Semiconductor Manufacturing to Advance its U.S. Expansion
[Picked up by 287 media titles]
2026-07-22 07:30Omni HR Launches Native MCP Integration, Connecting AI Assistants to Live HR Data
[Picked up by 286 media titles]
2026-07-20 11:00
Most Read
Singapore Tourism Board and Traveloka Renew Partnership to Welcome More Southeast Asian and Australian Travellers to Singapore
2026-07-17 18:18
14977
Ascentium Welcomes MGI Dobbyn Carafa, Strengthening Advisory Capability in Australia
2026-07-20 15:00
12087